Biogen Idec Inc.'s Tecfidera OK'd in Europe for MS

Biogen Idec (NASDAQ: BIIB  ) announced today that its drug Tecfidera has been approved for the treatment of patients with multiple sclerosis in European Union nations. It's been approved as a first-line oral treatment for people with relapsing-remitting multiple sclerosis (RRMS), the most common form of multiple sclerosis, according to the company.

"TECFIDERA exemplifies our commitment to deliver innovative therapies that help people living with serious diseases," Biogen Idec CEO George Scangos said in a press release.

Biogen Idec announced last March that Tecfidera had been approved as a first-line oral treatment of multiple sclerosis in the U.S. It is now the most prescribed treatment in the United States for forms of MS that involve relapsing after six months. The capsule was also approved in 2013 for use in both Canada and Australia.

Biogen Idec said today that the European Commission's approval was based on Tecfidera's clinically proven results, including one study in which patients have been tracked for six and a half years. It noted that the drug has been "shown to significantly reduce important measures of disease activity, including relapses and the development of brain lesions, as well as to slow disability progression, while demonstrating a favorable safety and tolerability profile."

When Biogen Idec reported third-quarter earnings in October 2013, it highlighted a 32% rise in revenue year over year to $1.8 billion. It attributed this gain largely to addition of Tecfidera to its portfolio of prescription drugs, as the MS drug had $286 million in revenue in the quarter.

When the earnings results were announced, Scangos said in a prepared statement that Tedfidera was valuable to patients and physicians and "we are pleased with how it has complemented our robust portfolio of MS therapies."

Scangos noted in today's announcement, "We already have seen TECFIDERA's significant impact on transforming the standard of care for MS where it is available and are excited to quickly bring its benefits to patients in the EU as well." 


Read/Post Comments (1) | Recommend This Article (1)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On February 04, 2014, at 7:57 AM, uncletom wrote:

    MAN! what a fall. is this a telling story of where we are headed in 2014. I feel like I should do something. I this Difered Compensation Plan really worth it?

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2820581, ~/Articles/ArticleHandler.aspx, 9/2/2015 8:59:41 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Patrick Morris

After a few stints in banking and corporate finance, Patrick joined the Motley Fool as a writer covering the financial sector. He's scaled back his everyday writing a bit, but he's always happy to opine on the latest headline news surrounding Berkshire Hathaway, Warren Buffett and all things personal finance.

Today's Market

updated 11 hours ago Sponsored by:
DOW 16,058.35 -469.68 0.00%
S&P 500 1,913.85 -58.33 0.00%
NASD 4,636.11 0.00 0.00%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/1/2015 4:00 PM
BIIB $292.50 Down -4.80 +0.00%
Biogen Idec CAPS Rating: ****